Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)

Johnson & Johnson's (JNJ) quarterly Income from Non-Controlling Interests came in at -$339.0 million in Q3 2012.

Analysis

Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends

Johnson & Johnson has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$339.0 million for Q3 2012.

  • In Q3 2012, Income from Non-Controlling Interests changed N/A year-over-year to -$339.0 million; the TTM figure through Dec 2013 stood at -$339.0 million (changed N/A YoY), while the FY2012 annual figure was -$339.0 million, changed N/A from the prior year.
  • Income from Non-Controlling Interests came in at -$339.0 million for Q3 2012 at Johnson & Johnson.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$339.0 million in Q3 2012 to a low of -$339.0 million in Q3 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 3.00 Mn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -7.00 Mn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 10.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -1.00 Mn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 39.52 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2012 -339.00 Mn